Clinical Trials Logo

Donor Lymphocyte Infusion clinical trials

View clinical trials related to Donor Lymphocyte Infusion.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03771222 Not yet recruiting - Relapse Clinical Trials

Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies

Start date: January 2019
Phase: Phase 2
Study type: Interventional

Unmanipulated allogenic peripheral blood stem cell transplantation (allo-PBSCT) has been an established treatment to cure high-risk leukemia/lymphoma. Relapse is the main cause of treatment failure for patients with relapsed/refractory disease or with very high-risk gene mutations such as TP53, TET2 and DNMT3a. Donor lymphocyte infusion (DLI) is an option to reduce relapse after allo-PBSCT for very high-risk disease without effective targeted therapy. In this study, the investigators aimed to compare the safety and efficacy of prophylactic DLI with G-CSF-primed peripheral blood progenitors for prevention of relapse after allo-PBSCT in patients with very high-risk leukemia/lymphoma.